Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bristol Myers

Bristol Myers Screams To A Year-High After Walloping Profit Expectations

Bristol Myers Squibb walloped profit expectations in the September quarter, and Bristol Myers stock screamed to a year-high.

Investors Business Daily

Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug

Cytokinetics said Monday its drug "significantly" improved exercise capacity in HCM patients. On Tuesday, Cytokinetics stock reversed higher.

Investors Business Daily

AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month

Cytokinetics has shucked off two high-profile setbacks, leading CYTK stock to double as it looks to take on Bristol in heart disease.

Investors Business Daily

Bristol Myers Stock Yo-Yoes, Trying To Avoid A Fourth Day In The Red, On So-So Earnings

Bristol Myers Squibb topped Wall Street's fourth-quarter expectations on Friday, but BMY stock yo-yoed and pulled back from strong gains.

Investors Business Daily

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%

Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.

Investors Business Daily

RayzeBio soars; Bristol Myers to pay $4.1 billion in second major buy in 3 days

Facing generic competition and looming patent losses, Bristol Myers is ending the year with a string of smaller drug company takeovers.

The Street

Read news from The Economist, FT, and more,
with one subscription

Bristol's $14 Billion Takeover Of Karuna Pulled A Bevy Of Stocks Higher

Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.

Investors Business Daily

Karuna Therapeutics soars after $14 billion takeover by Bristol Myers

Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimer's drugmaker Karuna Therapeutics for $14 billion.

The Street

Bristol Myers slumps as Bayer trial failure casts doubt on $5 billion drug

German drugmaker Bayer scrapped a late-stage trial of an experimental blood thinner that could have major implications for Bristol Myers.

The Street

Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone

Bristol Myers Squibb pushed back sales expectations for its new drugs by a year early Thursday, and BMY stock tumbled.

Investors Business Daily

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Price

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball price.

Investors Business Daily

Stocks slump, oil surges, Bristol Myers-Mirati deal, UAW Mack Truck strikes, Peltz eyes Disney seat - 5 Things To Know

Stocks lower, oil surges, Bristol Myers-Mirati, UAW strikes, Disney

The Street

Bristol Myers to buy cancer specialist Mirati for up to $5.8 billion

Bristol Myers will pay up to $5.8 billion for cancer-treatment specialists Mirati, the most recent oncology deal in the fast-moving pharma sector.

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?

Industry analysts warn that a groundbreaking change in how Medicare buys drugs threatens industry growth, profits — and maybe patient care.

Investors Business Daily

A Patent Cliff Is Coming For Bristol Myers — Can Billions In New Products Fill The Gap?

It's a new day at Bristol Myers, according to a company exec. But the drug giant's stock remains under pressure ahead of a patent cliff.

Investors Business Daily

Leading Health Stock With Rising Earnings Estimates Nears Buy Point

This top health stock stands out with its proven year-over-year earnings growth record, increased earnings estimates and hefty 2.7% dividend.

The Street

Bristol Myers Stock Higher As Opdivo, Eliquis Sales Power Q3 Earnings Beat

“Our strong results reflect growth of our in-line and new product portfolios,” said CEO Giovanni Caforio.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Bristol Myers Relies On 'Mature' Products For Narrow Quarterly Beat

Most of Bristol Myers' "mature" products delivered commanding third-quarter performances, an analyst said Wednesday as BMY stock rose.

Investors Business Daily

Cytokinetics CEO: Why It's OK Not Being An Overnight Success

Nobody will accuse Cytokinetics of being an overnight success, its chief executive says. But CYTK stock trades with enthusiasm on a near goal.

The Street

Bristol Myers Squibb Stock: Here's the Key Breakout Level to Watch

Bristol Myers Squibb received good news from the FDA, but only enough to put a key resistance level in play. Here's the level it needs to clear.

The Street

Bristol Myers Stock Surges After FDA Approves New Plaque Psoriasis Treatment; Amgen Slides

“We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis," said Bristol Myers' chief medical officer Samit Hirawat.

Investors Business Daily

S&P 500 Stock Market Winners Today

Oil stocks were S&P 500 winners Monday, including Diamondback Energy. Bristol Myers Squibb was among the big losers.

Investors Business Daily

Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops

Blood thinners produced by drug giants Bristol Myers and Bayer fell short of predictions, leading shares of both stocks down Monday.

The Street

Bristol Myers

"Secondary strokes continue to be a serious health risk for stroke patients and we believe these data demonstrated the potential of milvexian to address a key unmet need in this population," Bristol Myers said.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.